Soligenix (OTCQB: SNGX), a biopharmaceutical company focused on developing drugs to treat rare diseases, was granted a patent with this title: “Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity.” This patent protects its lead compound, SGX94, which contains dusquetide. Dusquetide is a synthetic IDR (detailed below) that regulates the body’s reaction to injury and infection towards an anti-inflammatory and an anti-infective response.
Plus, the company announced that along with Sciclone Pharmaceuticals, Inc. (SCLN), a US-based China-focused pharmaceutical company, agreed on a license agreement right for Sciclone to develop, promote, market, distribute and sell SGX942 (dusquetide). The terms of the deal dictate that Sciclone will make a $3 million investment in SNGX for 3,529,412 in the company’s common stock. In exchange for exclusive rights, SciClone will pay to Soligenix royalties on net sales, and Soligenix will supply commercial drug product to SciClone on a cost-plus basis, while maintaining worldwide manufacturing rights.
Dusquetide has tested positive in phase 2 results in the treatment of oral mucositis in head and neck cancer patients. Oral mucositis is one of the most common and difficult complications of cancer, which can lead to patients not eating and sores in the mucosa. In Phase 2 trials, studies showed a 50% decrease in oral mucositis for 111 patients. The company is fast tracking the drug for the above affliction, as well as for melioidosis, an infectious disease found in the soil.
These new patents broaden the scope of the IDR (innate defense regulator) technology platform. IDR’s are the newest and response to fighting various types of disease and infection. Here is Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, in the company press release, “The IDR technology utilizes a novel mechanism, and first-in-class compounds, to address the underlying role of innate immune dysregulation in a broad spectrum of disease indications, including many areas of unmet medical need. The patent estate, including this most recent patent granted in the US, establishes a platform to pursue or partner these indications, as circumstances allow.”
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer